97 related articles for article (PubMed ID: 25300476)
1. The age distribution of type-specific high-risk human papillomavirus incidence in two population-based screening trials.
Veldhuijzen NJ; Berkhof J; Gillio-Tos A; De Marco L; Carozzi F; Del Mistro A; Snijders PJ; Meijer CJ; Ronco G
Cancer Epidemiol Biomarkers Prev; 2015 Jan; 24(1):111-8. PubMed ID: 25300476
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
3. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy.
Dijkstra MG; van Niekerk D; Rijkaart DC; van Kemenade FJ; Heideman DA; Snijders PJ; Meijer CJ; Berkhof J
Cancer Epidemiol Biomarkers Prev; 2014 Jan; 23(1):55-63. PubMed ID: 23733907
[TBL] [Abstract][Full Text] [Related]
4. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.
Woestenberg PJ; King AJ; van Benthem BHB; Donken R; Leussink S; van der Klis FRM; de Melker HE; van der Sande MAB; Hoebe CJPA; Bogaards JA;
J Infect Dis; 2018 Jan; 217(2):213-222. PubMed ID: 29140439
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, incidence and persistence of genital HPV infections in a large cohort of sexually active young women in the Netherlands.
Mollers M; Boot Hein J; Vriend Henrike J; King Audrey J; van den Broek Ingrid VF; van Bergen Jan EA; Brink Antoinette AT; Wolffs Petra FG; Hoebe Christian JP; Meijer Chris JL; van der Sande Marianne AB; de Melker Hester E
Vaccine; 2013 Jan; 31(2):394-401. PubMed ID: 23146675
[TBL] [Abstract][Full Text] [Related]
6. High-risk human papillomavirus genotypes distribution in a cohort of HIV-positive women living in Europe: epidemiological implication for vaccination against human papillomavirus.
Konopnicki D; Manigart Y; Gilles C; Barlow P; De Marchin J; Feoli F; Delforge M; Clumeck N; De Wit S
AIDS; 2016 Jan; 30(3):425-33. PubMed ID: 26765936
[TBL] [Abstract][Full Text] [Related]
7. Very low human Papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests.
Zhao C; Elishaev E; Yuan KH; Yu J; Austin RM
Cancer; 2007 Oct; 111(5):292-7. PubMed ID: 17879368
[TBL] [Abstract][Full Text] [Related]
8. Population-based evaluation of type-specific HPV prevalence among women in British Columbia, Canada.
Ogilvie GS; Cook DA; Taylor DL; Rank C; Kan L; Yu A; Mei W; van Niekerk DJ; Coldman AJ; Krajden M
Vaccine; 2013 Feb; 31(7):1129-33. PubMed ID: 23273510
[TBL] [Abstract][Full Text] [Related]
9. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
[TBL] [Abstract][Full Text] [Related]
10. High-risk HPV type-specific clearance rates in cervical screening.
Bulkmans NW; Berkhof J; Bulk S; Bleeker MC; van Kemenade FJ; Rozendaal L; Snijders PJ; Meijer CJ;
Br J Cancer; 2007 May; 96(9):1419-24. PubMed ID: 17342094
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
de Sanjose S; Quint WG; Alemany L; Geraets DT; Klaustermeier JE; Lloveras B; Tous S; Felix A; Bravo LE; Shin HR; Vallejos CS; de Ruiz PA; Lima MA; Guimera N; Clavero O; Alejo M; Llombart-Bosch A; Cheng-Yang C; Tatti SA; Kasamatsu E; Iljazovic E; Odida M; Prado R; Seoud M; Grce M; Usubutun A; Jain A; Suarez GA; Lombardi LE; Banjo A; Menéndez C; Domingo EJ; Velasco J; Nessa A; Chichareon SC; Qiao YL; Lerma E; Garland SM; Sasagawa T; Ferrera A; Hammouda D; Mariani L; Pelayo A; Steiner I; Oliva E; Meijer CJ; Al-Jassar WF; Cruz E; Wright TC; Puras A; Llave CL; Tzardi M; Agorastos T; Garcia-Barriola V; Clavel C; Ordi J; Andújar M; Castellsagué X; Sánchez GI; Nowakowski AM; Bornstein J; Muñoz N; Bosch FX;
Lancet Oncol; 2010 Nov; 11(11):1048-56. PubMed ID: 20952254
[TBL] [Abstract][Full Text] [Related]
12. The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix.
Zielinski GD; Snijders PJ; Rozendaal L; Daalmeijer NF; Risse EK; Voorhorst FJ; Jiwa NM; van der Linden HC; de Schipper FA; Runsink AP; Meijer CJ
J Pathol; 2003 Dec; 201(4):535-43. PubMed ID: 14648656
[TBL] [Abstract][Full Text] [Related]
13. Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate.
Bulkmans NW; Bulk S; Ottevanger MS; Rozendaal L; Hellenberg SM; van Kemenade FJ; Snijders PJ; Boeke AJ; Meijer CJ
J Clin Pathol; 2006 Nov; 59(11):1218-20. PubMed ID: 16943223
[TBL] [Abstract][Full Text] [Related]
14. Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.
Carozzi F; De Marco L; Gillio-Tos A; Del Mistro A; Girlando S; Baboci L; Trevisan M; Burroni E; Grasso S; Giorgi Rossi P; Ronco G;
J Clin Virol; 2014 Jul; 60(3):257-63. PubMed ID: 24815381
[TBL] [Abstract][Full Text] [Related]
15. HIV associated high-risk HPV infection among Nigerian women.
Akarolo-Anthony SN; Al-Mujtaba M; Famooto AO; Dareng EO; Olaniyan OB; Offiong R; Wheeler CM; Adebamowo CA
BMC Infect Dis; 2013 Nov; 13():521. PubMed ID: 24192311
[TBL] [Abstract][Full Text] [Related]
16. Re-detection vs. new acquisition of high-risk human papillomavirus in mid-adult women.
Fu TC; Carter JJ; Hughes JP; Feng Q; Hawes SE; Schwartz SM; Xi LF; Lasof T; Stern JE; Galloway DA; Koutsky LA; Winer RL
Int J Cancer; 2016 Nov; 139(10):2201-12. PubMed ID: 27448488
[TBL] [Abstract][Full Text] [Related]
17. Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study.
Carozzi F; Ronco G; Gillio-Tos A; De Marco L; Del Mistro A; Girlando S; Franceschi S; Plummer M; Vaccarella S;
Eur J Cancer; 2012 Jul; 48(11):1633-7. PubMed ID: 22088483
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Cryotherapy on Human Papillomavirus Clearance Among HIV-Positive Women in Lusaka, Zambia.
Katundu K; Bateman AC; Pfaendler KS; Mwanahamuntu MH; Kapambwe S; Vermund SH; Sahasrabuddhe VV; Msadabwe SC; Stringer JS; Parham GP; Chibwesha CJ
J Low Genit Tract Dis; 2015 Oct; 19(4):301-6. PubMed ID: 26125097
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of HPV infection and current status of cervical cancer prevention in Greece: final results of the LYSISTRATA cross-sectional study.
Agorastos T; Chatzistamatiou K; Zafrakas M; Siamanta V; Katsamagkas T; Constantinidis TC; Lampropoulos AF;
Eur J Cancer Prev; 2014 Sep; 23(5):425-31. PubMed ID: 24977385
[TBL] [Abstract][Full Text] [Related]
20. Incidence, clearance and predictors of human papillomavirus infection in women.
Sellors JW; Karwalajtys TL; Kaczorowski J; Mahony JB; Lytwyn A; Chong S; Sparrow J; Lorincz A;
CMAJ; 2003 Feb; 168(4):421-5. PubMed ID: 12591782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
